Lilly to acquire Verve in $1B bet on gene editing for heart disease

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also follows a yearslong in decline in Verve’s share price amid skepticism over the need for such a therapy. 

Jun 17, 2025 - 16:20
 0
Lilly to acquire Verve in $1B bet on gene editing for heart disease

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also follows a yearslong in decline in Verve’s share price amid skepticism over the need for such a therapy.